Traditional 510(k) | DigniShield Stool Management System

510(k) Summary

Bard Medical Division C.R. Bard, Inc. 8195 Industrial Blvd. Covington, GA 30014



510(k) Summary

In accordance with 21 CFR §807.92 and the Safe Medical Devices Act of 1990, the following information is provided for the DigniShield Stool Management System 510(k) premarket notification. The submission was prepared in accordance with the FDA guidance document, 'Format for Traditional and Abbreviated 510(k)s', issued on August 12, 2005.

Sponsor: BARD Medical Division

C. R. BARD, Inc. 8195 Industrial Blvd. Covington, GA 30014

Establishment Registration Number: 1018233

Contact: Michele Davis, RAC

Regulatory Affairs Project Manager

Bard Medical Division Tel: 770-784-6274 Fax: 770-385-4706

Date: May 8, 2014

Subject Device: Trade Name: Bard® DigniShield® Stool Management System

Common Name: Rectal catheter

Classification Name: Gastrointestinal tube and accessories

Regulation: 21 CFR 876.5980

Classification: Class II
Product Code: KNT

Legally marketed devices to which substantial equivalence is claimed:

- Bard® DigniShield® Stool Management System, K102391
- Bard® DigniCare Stool Management System, K073598
- ConvaTec Flexi-Seal® Signal™ Fecal Management System, K112342
- Hollister InstaFlo Bowel Catheter System Kit, K123804

Device Description

The Bard® DigniShield® Stool Management System is sold as a tray (kit) including a catheter, collection bag and stand alone components. The catheter consists of a retention cuff, transsphincteric zone, drainage tubing, inflation arm, irrigation arm, flush arm and piston valve connector. The retention cuff and trans-sphincteric zone are constructed from silicone and the drainage tubing is constructed from a Thermoplastic Elastomer (TPE) material. The system includes a collection bag which is manufactured from the same TPE material as the drainage tubing. The collection bag interfaces with the catheter and allows for the collection of fecal

medication during administration of medication. The syringe is used to facilitate the inflation of the cuff portion of the catheter. The lubricating jelly is provided to minimize patient discomfort and irritation of the rectum while the device is being inserted into the rectal vault. The biological matter. Additionally, the tray (kit) contains a tube clamp, syringe, lubricating jelly and odor eliminator. The tube clamp is used to retain odor eliminator may be used as an air freshener in the room.

Intended Use

The Bard® DigniShield® Stool Management System with odor barrier properties is intended for fecal management by diverting and collecting liquid or semi-liquid stool to minimize skin contact in bedridden patients and to provide access for the administration of medications. Adult use only.

Summary of Technological Characteristics

The table below summarizes the technological characteristics of the device as compared to the predicate devices.

| Characteristic | Subject Device | Predicate Device | Predicate Device | Predicate Device | Predicate Device |
|-----------------------|--------------------------|--------------------------|--------------------------|--------------------------|----------------------------|
| | and an arrive | (K102391) | (K073598) | (K112342) | (K123804) |
| Nome | Bard DigniShield Stool | Bard DigniShield Stool, | Bard DigniCare Stool | Flexi-Seal Signal Fecal | Hollister InstaFlo Bowel |
| ואסוווכ | Management System | Management System | Management System | Management System | Catheter System Kit |
| Intended Use | Fecal management |
| | Bard DigniShield Stool | Bard DigniShield Stool | Bard DigniShield Stool | For use to manage fecal | A bowel catheter |
| | Management System | Management System is | Management System is | incontinence through | system kit with odor |
| | with odor barrier | intended for fecal | intended for fecal | the collection of liquid | barrier properties for |
| - | properties is intended | management by • | management by | to semi-liquid stool and | diversion of liquid or |
| | for fecal management | diverting and collecting | diverting and collecting | to provide access to | semi-liquid stool to |
| | by diverting and | liquid or semi-liquid | liquid or semi-liquid | administer medications | facilitate the collection |
| on the section of the | collecting liquid or | stool to minimize skin | stool to minimize skin | | of fecal matter in |
| mulcations for ose | semi-liquid stool to | contact in bedridden | contact in bedridden | | patients with little or no |
| | minimize skin contact in | patients. Adult use | patients. Adult use | | bowel control. |
| | bedridden patients and | only. | only. | | • |
| | to provide access for | | | | |
| | the administration of | | | | |
| | medications. Adult use | | | | |
| | only. | | | | |

| 1,1 | | Predicate Device | Predicate Device | Predicate Device | Predicate Device |
|-------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| Characteristic | and to a control | (K102391) | (K073598) | (K112342) | (K123804) |
| A com c l A | Bard DigniShield Stool | Bard DigniShield Stool | Bard DigniCare Stool | Flexi-Seal Signal Fecal | Hollister InstaFlo Bowel |
| Manie | Management System | Management System | Management System | Management System | Catheter System Kit |
| Device use, Sterility, | Sterile Use, Non Sterile, |
| Max Usage of Device | 29 days |
| Odor Barrier Properties | Yes | No | No | No | Yes |
| Medication Delivery | Yes | ON | No | Yes | No |
| Cathotor Matorial | Thermoplastic | Thermoplastic | Silicone | Silicone | Thermoplastic |
| במתובובן ואומוביוומו | Elastomer and Silicone | Elastomer | | | |
| | Collection Bag | Collection Bag | Collection Bag | Collection Bag (3) | Collection Bag |
| | Syringe | Syringe | Syringe | Syringe | Syringe |
| Accessories | Lubricating Jelly | Lubricating Jelly | Lubricating Jelly | Cinch Clamp | |
| | Odor Eliminator | Odor Eliminator | Odor Eliminator | | |
| | Tube Clamp | | | | : |

Summary of Performance (Non-Clinical Testing) Data:

equivalent to the predicate devices for dimensional, functional and strength testing. Non-clinical performance testing supports that the subject Non-clinical testing of the subject device for functional and structural characteristics has been performed. The subject device was substantially device is substantially equivalent to the predicate device for administration of medication. Non-clinical odor barrier testing demonstrates the subject device decrease in odor permeation is substantially equivalent to the predicate device.

subject device tube clamp met the requirements for a skin contacting device with limited exposure per ISO 10993-1:2009, Biological evaluation Biocompatibility testing of the subject device catheter met the requirements for a mucosal contacting device with prolonged exposure and the of medical devices and testing within a risk management process and FDA Bluebook Memorandum G95-1, Use of International Standard ISO 10993 Biological Evaluation of Medical Devices Part 1: Evaluation of Testing (May 1, 1995).

The subject device has been shown to be as safe and effective and substantially equivalent to the legally marketed, predicate devices.



Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WQ66-G609 Silver Spring, MD 20993-0002

May 9, 2014

C.R. Bard, Inc. Michele Davis Regulatory Affairs Project Manager 8195 Industrial Blvd. Covington, GA 30014

Re: K133251

Trade/Device Name: DigniShield Stool Management System

Regulation Number: 21 CFR§ 876.5980

Regulation Name: Gastrointestinal tube and accessories

Regulatory Class: II Product Code: KNT Dated: April 4, 2014 Received: April 7, 2014

Dear Michele Davis.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. However, you are responsible to determine that the medical devices you use as components in the kit have either been determined as substantially equivalent under the premarket notification process (Section 510(k) of the act), or were legally on the market prior to May 28, 1976, the enactment date of the Medical Device Amendments. Please note: If you purchase your device components in bulk (i.e., unfinished) and further process (e.g., sterilize) you must submit a new 510(k) before including these components in your kit. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Joyce M. Whang -S

for Benjamin R. Fisher, Ph.D.
Director
Division of Reproductive, Gastro-Renal,
and Urological Devices
Office of Device evaluation
Center for Devices and radiological Health

Enclosure

Section 4

Indications for Use Statement

| 510(k) Number: | K133251 | · | | |
|---|--------------------------|---|--|--|
| Device Name: | DigniShield Stool Manage | ement System | | |
| INDICATIONS FOR USE: The Bard® DigniShield® Stool Management System with odor barrier properties is intended for fecal management by diverting and collecting liquid or semi-liquid stool to minimize skin contact in bedridden patients and to provide access for the administration of medications. | | | | |
| Adult use only. | | | | |
| Prescription Use (Part 21 CFR 801, Subpart | and/or D) | Over-the-Counter Use (21 CFR 807 Subpart C) | | |
| (Please do not write below this line – continue on another page if needed) | | | | |

Concurrence of CDRH, Office of Device Evaluation (ODE)

Joyce M. Whang -S